Diabetic retinopathy and coronary implantation of sirolimus-eluting stents.

INTRODUCTION The prognostic value of identifying the retinal status of diabetic patients undergoing coronary implantation of drug-eluting stents is unknown. METHODS We evaluated the outcomes of 318 consecutive patients undergoing implantation of sirolimus-eluting stents for coronary artery disease. Patients were divided into 5 groups according to the diabetic and retinal status: diabetic patients without retinopathy (43 patients); diabetic patients with nonproliferative retinopathy (34); diabetic patients with proliferative retinopathy (37); diabetic patients with unknown retinal status (30); and nondiabetic patients (174). RESULTS During a mean follow-up of 385 days, 64 patients had target-vessel failure (defined as a composite of death from cardiac causes, myocardial infarction, and target-vessel revascularization). At 1 year, Kaplan-Meier estimates of the rate of target-vessel failure were 15.3% for diabetic patients without retinopathy, 56.6% for those with nonproliferative retinopathy, 17.3% for those with proliferative retinopathy, 19.0% for those with unknown retinal status, and 16.0% for nondiabetic patients. After adjustment for the potential confounders and differences between groups, the relation of nonproliferative retinopathy to target-vessel failure remained significant. In an analysis in which diabetic patients without retinopathy were used as the reference group, the hazard ratios for target-vessel failure were 3.9 for those with nonproliferative retinopathy, 1.3 for those with proliferative retinopathy, 1.1 for those with unknown retinal status, and 1.4 for nondiabetic patients (P for trend = 0.015). CONCLUSIONS As compared with diabetic patients without retinopathy, those with nonproliferative retinopathy have an increased risk for target-vessel failure after coronary implantation of sirolimus-eluting stents.

[1]  A. Schachat,et al.  Long-term survival rate after vitreous surgery for complications of diabetic retinopathy. , 1991, Ophthalmology.

[2]  S. Ohno,et al.  Survival rate after vitreous surgery in patients with diabetic retinopathy. , 1993, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[3]  A. Colombo,et al.  Impact of microvascular complications on outcome after coronary stent implantations in patients with diabetes. , 2005, Journal of the American College of Cardiology.

[4]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[5]  E. Agardh,et al.  Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12‐year observation study of 462 patients , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[6]  M. Ono,et al.  Impact of diabetic retinopathy on cardiac outcome after coronary artery bypass graft surgery: prospective observational study. , 2006, The Annals of thoracic surgery.

[7]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[8]  P. Sullivan,et al.  Long‐term Outcome After Photocoagulation for Proliferative Diabetic Retinopathy , 1990, Diabetic medicine : a journal of the British Diabetic Association.

[9]  Lawrence Joseph,et al.  A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents , 2004, The Lancet.

[10]  J. Sparrow,et al.  Co-morbidity in patients with sight-threatening diabetic retinopathy , 2001, Eye.

[11]  R. Klein,et al.  Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. , 2004, Archives of internal medicine.

[12]  L. Groop,et al.  Mortality in Diabetic Patients Participating in an Ophthalmological Control and Screening Programme , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[13]  M. Laakso,et al.  Retinopathy Predicts Coronary Heart Disease Events in NIDDM Patients , 1996, Diabetes Care.

[14]  G. Lip,et al.  Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. , 2000, Investigative ophthalmology & visual science.

[15]  R. Klein,et al.  Association of ocular disease and mortality in a diabetic population. , 1999, Archives of ophthalmology.

[16]  A. Kastrati,et al.  Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.

[17]  I. Shiojima,et al.  The role of vascular endothelial growth factor in restenosis: the controversy continues. , 2004, Circulation.

[18]  S. Kitamura,et al.  The impact of diabetic retinopathy on long-term outcome following coronary artery bypass graft surgery. , 2002, Journal of the American College of Cardiology.

[19]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[20]  Charles L. Brown,et al.  Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.

[21]  A. Kastrati,et al.  Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. , 2005, The New England journal of medicine.

[22]  R Hiller,et al.  Blindness caused by diabetic retinopathy. , 1974, American journal of ophthalmology.

[23]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[24]  D. Hewett‐Emmett,et al.  Mortality of Mexican Americans With NIDDM: Retinopathy and other predictors in Starr County, Texas , 1993, Diabetes Care.